페이지 정보
본문
Personalized Depression TreatmentTraditional treatment and medications don't work for a majority of people who are depressed. A customized treatment could be the solution.
Cue is an intervention platform that transforms sensor data collected from smartphones into personalised micro-interventions for improving mental health. We parsed the best-fit personalized ML models for each subject using Shapley values to understand their feature predictors and reveal distinct characteristics that can be used to predict changes in mood with time.
Predictors of Mood
depression treatment facility is one of the most prevalent causes of mental illness.1 Yet, only half of those suffering from the condition receive treatment1. In order to improve outcomes, doctors must be able to identify and treat patients who have the highest probability of responding to specific treatments.
Personalized depression treatment is one method to achieve this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will gain the most from certain treatments. They make use of sensors on mobile phones, a voice assistant with artificial intelligence and other digital tools. Two grants were awarded that total over $10 million, they will use these tools to identify biological and behavioral predictors of response to antidepressant medications and psychotherapy.
The majority of research into predictors of depression treatment effectiveness has focused on the sociodemographic and clinical aspects. These include demographics like gender, age and education as well as clinical characteristics like symptom severity and comorbidities, as well as biological markers.
While many of these factors can be predicted by the information in medical records, few studies have used longitudinal data to determine the causes of mood among individuals. Few studies also take into account the fact that moods can vary significantly between individuals. It is therefore important to develop methods that allow for the identification and quantification of individual differences in mood predictors, treatment effects, etc.
The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to develop algorithms that can detect various patterns of behavior and emotion that are different between people.
The team also created a machine learning algorithm to model dynamic predictors for each person's depression mood. The algorithm combines these individual differences into a unique "digital phenotype" for each participant.
This digital phenotype was found to be associated with CAT-DI scores, a psychometrically validated scale for assessing severity of symptom. However the correlation was tinny (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 x 10-03) and varied widely among individuals.
Predictors of symptoms
Depression is the leading reason for disability across the world1, but it is often not properly diagnosed and treated. In addition an absence of effective interventions and stigma associated with depression disorders hinder many individuals from seeking help.
To allow for individualized treatment to improve treatment, identifying the patterns that can predict symptoms is essential. The current methods for predicting symptoms rely heavily on clinical interviews, which are not reliable and only reveal a few characteristics that are associated with depression.
Machine learning can improve the accuracy of the diagnosis and treatment of depression by combining continuous, digital behavioral phenotypes collected from smartphone sensors with a validated mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes provide a wide range of unique behaviors and activities, which are difficult to document through interviews and permit continuous and high-resolution measurements.
The study involved University of California Los Angeles students who had mild to severe alcohol depression treatment symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA post pregnancy depression treatment Grand Challenge. Participants were referred to online support or in-person clinical care in accordance with their severity of depression. Patients who scored high on the CAT DI of 35 or 65 were given online support via the help of a coach. Those with a score 75 were routed to clinics in-person for psychotherapy.
At the beginning, participants answered the answers to a series of questions concerning their personal demographics and psychosocial characteristics. The questions included education, age, sex and gender and marital status, financial status and whether they were divorced or not, current suicidal thoughts, intentions or attempts, and how often they drank. The CAT-DI was used to assess the severity of depression-related symptoms on a scale ranging from 100 to. The CAT-DI assessment was performed every two weeks for those who received online support, and weekly for those who received in-person support.
Predictors of natural treatment depression anxiety Response
Research is focused on individualized depression treatment. Many studies are focused on finding predictors, which can aid clinicians in identifying the most effective drugs to treat each patient. Particularly, pharmacogenetics can identify genetic variants that influence how the body metabolizes antidepressants. This allows doctors select medications that are most likely to work for each patient, while minimizing time and effort spent on trials and errors, while avoid any negative side effects.
Another approach that is promising is to build prediction models using multiple data sources, combining clinical information and neural imaging data. These models can be used to identify which variables are the most likely to predict a specific outcome, like whether a medication will help with symptoms or mood. These models can be used to determine the patient's response to treatment, allowing doctors to maximize the effectiveness.
A new generation of machines employs machine learning techniques such as algorithms for classification and supervised learning such as regularized logistic regression, and tree-based techniques to combine the effects of several variables and increase the accuracy of predictions. These models have been shown to be effective in predicting treatment outcomes like the response to antidepressants. These methods are becoming more popular in psychiatry and will likely become the norm in the future clinical practice.
In addition to ML-based prediction models The study of the mechanisms behind depression is continuing. Recent findings suggest that the disorder is associated with dysfunctions in specific neural circuits. This suggests that an the treatment for depression will be individualized focused on treatments that target these circuits to restore normal function.
One method to achieve this is to use internet-based interventions that can provide a more individualized and tailored experience for patients. For instance, one study found that a web-based program was more effective than standard treatment in improving symptoms and providing the best quality of life for patients with MDD. A controlled study that was randomized to a customized treatment for depression revealed that a substantial percentage of participants experienced sustained improvement and had fewer adverse negative effects.
Predictors of adverse effects
A major challenge in personalized depression treatment involves identifying and predicting the antidepressant medications that will have very little or no side effects. Many patients take a trial-and-error approach, with several medications prescribed until they find one that is safe and effective. Pharmacogenetics provides a novel and exciting method of selecting antidepressant medications that is more efficient and targeted.
There are several variables that can be used to determine the antidepressant that should be prescribed, including gene variations, phenotypes of patients like gender or ethnicity and comorbidities. To determine the most reliable and reliable predictors for a particular treatment, controlled trials that are randomized with larger numbers of participants will be required. This is due to the fact that it can be more difficult to determine interactions or moderators in trials that only include one episode per participant rather than multiple episodes over time.
Additionally the prediction of a patient's response to a particular medication will also likely need to incorporate information regarding comorbidities and symptom profiles, in addition to the patient's personal experiences with the effectiveness and tolerability of the medication. At present, only a handful of easily identifiable sociodemographic variables and clinical variables appear to be reliably related to response to MDD. These include gender, age, race/ethnicity as well as BMI, SES and the presence of alexithymia.
The application of pharmacogenetics in treatment for depression is in its infancy, and many challenges remain. First, a clear understanding of the genetic mechanisms is essential and a clear definition of what constitutes a reliable predictor for treatment response. In addition, ethical concerns, such as privacy and the ethical use of personal genetic information must be carefully considered. In the long term the use of pharmacogenetics could provide an opportunity to reduce the stigma that surrounds mental health treatment and improve the treatment for anxiety and depression near me outcomes for patients with depression. As with any psychiatric approach it is crucial to carefully consider and implement the plan. At present, the most effective option is to provide patients with an array of effective medications for depression and encourage them to speak with their physicians about their experiences and concerns.댓글목록
등록된 댓글이 없습니다.